帳號: 密碼:
記住我 忘記密碼?

 
個人資料
編號: 1601483914
姓名: 那份宿醉的美
人氣: 1040
 
經紀人資料
威望:
 
誰來我家

mhong

poerunds

朱歌哥

Glen
 
首頁 日記 相簿 備份日記 留言板
 
 
 那份宿醉的美 » 所有日記 » 未分類
0
1

那份宿醉的美
Use of chemotherapy for early stage brea
2018-05-11  晴空萬里
台北市
The findings reflect a growing acknowledgement by oncologists and patients that for some women, the harms of chemotherapy may outweigh its potential benefits. The study also revealed that physicians are more likely to turn to tumor genomic testing when a patient expresses a treatment preference that doesn't match her physician's recommendations Varicella associated pneumonia.
 
"For patients with early stage breast cancer, we've seen a significant decline in chemotherapy use over the last few years without a real change in evidence," said Allison Kurian, MD, associate professor of medicine and of health research and policy at Stanford. "This likely reflects a change in the culture of how physicians are practicing, and a move toward using tumor biology to guide treatment choices rather than solely relying on clinical measures."
 
Kurian is the lead author of the study, which will be published online Dec. 11 in the Journal of the National Cancer Institute. Steven Katz, MD, MPH, professor of medicine and of health management and policy at the University of Michigan, is the senior author.

Visit site offering the best portable vaporizer and medical vaping device! A medical vaping device is joined at the hip of a medical marijuana user! Transpring offers differents vaping devices for medical purpose.
 
"Our study shows how breast cancer is a model for how doctors have driven advances in personalized medicine into the exam room to reduce overtreatment," said Katz.
 
Surveying women, oncologists
 
The researchers surveyed 5,080 women treated for early stage breast cancer between 2013 and 2015 in Georgia and Los Angeles. Among them, 2,926 had stage-1 or -2 breast cancers that were positive for estrogen receptor expression and negative for human epidermal growth factor receptor-2 expression. (Receptor expression status is often used to guide treatment recommendations for women with breast cancer.)
 
After categorizing the women based on the involvement of neighboring lymph nodes, the researchers asked them whether their oncologists had recommended chemotherapy and whether they had received it. The researchers also surveyed 504 of the oncologists treating these early stage breast cancer patients about how they decided whether to recommend chemotherapy for the patients.
 
Kurian and her colleagues found that from 2013 to 2015, there was a decrease from 34.5 percent to 21.3 percent in chemotherapy use in study participants. During the same period, the participants reported a decline in chemotherapy recommendations by their oncologists from 44.9 percent to 31.6 percent.
 
Chemotherapy use in patients with no lymph node involvement declined from 26.6 percent to 14.1 percent; in patients with lymph node involvement, it declined from 81.1 percent to 64.2 percent.
 
Finally, 67.4 percent of oncologists surveyed indicated they would order tumor genomic testing to estimate a lymph node-positive woman's risk of cancer recurrence if the woman disagreed with her doctor's recommendation to receive chemotherapy. In contrast, only 17.5 percent would order the test if the patient and doctor were in agreement about her course of treatment.
 
"We believe this study indicates that physicians are attempting to be more selective in their recommendations and to spare patients toxicity when possible," said Kurian. "As personalized medicine becomes more widely available, doctors are using test results as part of their dialogue with patients about their preferences and overall treatment goals. But the long-term outcomes of these recent changes in chemotherapy use are uncertain."

Cooking with Dry aged beef, visit our website to find a variety of steak recipes with asian and western flavours. Heat up a wok and try these hidden and tasty recipes, with the best quality of European beef.


這篇日記發生在...台北市信義區
請輸入5個字以上的留言(已輸入0個字) 

共有筆,第1-50
 
 
 
runtime:0.019583sec